PL2797581T3 - Formulacje (+)-2-[1-(3-etoksy-4-metoksy-fenylo)-2-metanosulfonylo-etylo]- 4acetyloaminoizoindolino-1,3-dionu - Google Patents

Formulacje (+)-2-[1-(3-etoksy-4-metoksy-fenylo)-2-metanosulfonylo-etylo]- 4acetyloaminoizoindolino-1,3-dionu

Info

Publication number: PL2797581T3
Authority: PL; Poland
Prior art keywords: acetylaminoisoindoline; methanesulfonyl; dione; ethoxy; methoxy
Prior art date: 2011-12-27

Application number

PL12808662T

Other languages

English (en)

Inventor

Sreenivas S. Bhat

Michael T. Kelly

Original Assignee

Amgen (Europe) GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-12-27

Filing date

2012-12-26

Publication date

2020-10-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47459206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2797581(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-12-26 Application filed by Amgen (Europe) GmbH filed Critical Amgen (Europe) GmbH

2020-10-05 Publication of PL2797581T3 publication Critical patent/PL2797581T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Inorganic Chemistry (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Indole Compounds (AREA)

PL12808662T 2011-12-27 2012-12-26 Formulacje (+)-2-[1-(3-etoksy-4-metoksy-fenylo)-2-metanosulfonylo-etylo]- 4acetyloaminoizoindolino-1,3-dionu PL2797581T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161580626P	2011-12-27	2011-12-27
PCT/US2012/071623 WO2013101810A1 (en)	2011-12-27	2012-12-26	Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
EP12808662.6A EP2797581B1 (en)	2011-12-27	2012-12-26	Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione

Publications (1)

Publication Number	Publication Date
PL2797581T3 true PL2797581T3 (pl)	2020-10-05

Family

ID=47459206

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL20172615.5T PL3756650T3 (pl)	2011-12-27	2012-12-26	Formulacje (+)-2-[1-(3-etoksy-4-metoksy-fenylo)-2-metanosulfonylo-etylo]-4-acetyloaminoizoindolino-1,3-dionu
PL12808662T PL2797581T3 (pl)	2011-12-27	2012-12-26	Formulacje (+)-2-[1-(3-etoksy-4-metoksy-fenylo)-2-metanosulfonylo-etylo]- 4acetyloaminoizoindolino-1,3-dionu

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL20172615.5T PL3756650T3 (pl)	2011-12-27	2012-12-26	Formulacje (+)-2-[1-(3-etoksy-4-metoksy-fenylo)-2-metanosulfonylo-etylo]-4-acetyloaminoizoindolino-1,3-dionu

Country Status (34)

Country	Link
US (2)	US20130164376A1 (pl)
EP (3)	EP4623993A3 (pl)
JP (1)	JP6161629B2 (pl)
KR (3)	KR102035362B1 (pl)
CN (1)	CN104136003A (pl)
AU (1)	AU2012362562B2 (pl)
BR (1)	BR112014015923B1 (pl)
CA (1)	CA2861594A1 (pl)
CL (1)	CL2014001726A1 (pl)
CO (1)	CO7000777A2 (pl)
CR (1)	CR20140314A (pl)
CY (1)	CY1123174T1 (pl)
DK (2)	DK2797581T3 (pl)
EA (1)	EA027801B1 (pl)
EC (1)	ECSP14007965A (pl)
ES (2)	ES2799448T3 (pl)
FI (1)	FI3756650T3 (pl)
HR (2)	HRP20200825T1 (pl)
HU (2)	HUE050327T2 (pl)
IL (1)	IL233296B (pl)
LT (2)	LT3756650T (pl)
MX (2)	MX373934B (pl)
NI (1)	NI201400068A (pl)
PE (1)	PE20142318A1 (pl)
PH (1)	PH12014501495A1 (pl)
PL (2)	PL3756650T3 (pl)
PT (2)	PT3756650T (pl)
RS (2)	RS60415B1 (pl)
SG (2)	SG11201403564YA (pl)
SI (2)	SI2797581T1 (pl)
SM (2)	SMT202000339T1 (pl)
UA (1)	UA113750C2 (pl)
WO (1)	WO2013101810A1 (pl)
ZA (1)	ZA201404629B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013040120A1 (en)	2011-09-14	2013-03-21	Celgene Corporation	Formulations of cyclopropanecarboxylic acid {2-(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amidecelgene corporation state of incorporation:delaware
PL3756650T3 (pl)	2011-12-27	2026-01-19	Amgen (Europe) GmbH	Formulacje (+)-2-[1-(3-etoksy-4-metoksy-fenylo)-2-metanosulfonylo-etylo]-4-acetyloaminoizoindolino-1,3-dionu
US9994522B2 (en)	2014-05-11	2018-06-12	Mapi Pharma Ltd.	Amorphous form of apremilast
EP3174999A1 (en)	2014-07-29	2017-06-07	Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca	Differential diagnosis and therapy selection for rheumatoid arthritis and psoriatic arthritis
CA2987912C (en) *	2015-06-30	2023-01-24	Genentech, Inc.	Immediate-release tablets containing a drug and processes for forming the tablets
CZ20165A3 (cs) *	2016-01-06	2017-07-19	Zentiva, K.S.	Způsoby přípravy amorfního apremilastu
BR112018076114A2 (pt)	2016-06-15	2019-03-26	Torrent Pharmaceuticals Limited	composições tópicas de apremilast
JP2022537877A (ja) *	2019-04-30	2022-08-31	セルジーンコーポレイション	アプレミラストおよびｔｙｋ２阻害剤を含む併用療法
ES2823927B2 (es) *	2019-11-07	2022-01-18	Beijing Enbiwo Biological Tech Co Ltd	Composición en tamaño micrométrico y su uso como agente coadyuvante de alcaloides vegetales
KR20220047105A (ko)	2020-10-08	2022-04-15	주식회사 엔비피헬스케어	아프레밀라스트를 함유하는 약학 조성물
CN112245403B (zh) *	2020-10-23	2022-04-22	杭州朱养心药业有限公司	磷酸二酯酶-4抑制剂及其口服固体组合物
EP4183389A1 (en)	2021-11-18	2023-05-24	KRKA, d.d., Novo mesto	Pharmaceutical composition comprising apremilast
WO2023118043A1 (en)	2021-12-22	2023-06-29	Biohorm, S.L.	Pharmaceutical compositions of apremilast

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5358941A (en) *	1992-12-02	1994-10-25	Merck & Co., Inc.	Dry mix formulation for bisphosphonic acids with lactose
WO1995003009A1 (en)	1993-07-22	1995-02-02	Oculex Pharmaceuticals, Inc.	Method of treatment of macular degeneration
US5770589A (en)	1993-07-27	1998-06-23	The University Of Sydney	Treatment of macular degeneration
EP0716597A1 (en)	1993-08-30	1996-06-19	Warner-Lambert Company	Tablet coating based on a melt-spun mixture of a saccharide and apolymer
IT1274549B (it)	1995-05-23	1997-07-17	Indena Spa	Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
US5800819A (en)	1996-01-25	1998-09-01	National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology	Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
HU228769B1 (en)	1996-07-24	2013-05-28	Celgene Corp	Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
KR100534498B1 (ko)	1996-07-24	2005-12-08	셀진 코포레이션	치환된 2-(2,6-디옥소피페리딘-3-일)-프탈이미드와 치환된 2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린과 ＴＮＦα농도를 감소시키는 방법
US6281230B1 (en)	1996-07-24	2001-08-28	Celgene Corporation	Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en)	1996-07-24	1999-06-29	Celgene Corp	Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6015803A (en)	1998-05-04	2000-01-18	Wirostko; Emil	Antibiotic treatment of age-related macular degeneration
US6225348B1 (en)	1998-08-20	2001-05-01	Alfred W. Paulsen	Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en)	1998-09-03	1999-12-14	Protein Technologies International, Inc.	Method for inhibiting or reducing the risk of macular degeneration
US6020358A (en)	1998-10-30	2000-02-01	Celgene Corporation	Substituted phenethylsulfones and method of reducing TNFα levels
US6448323B1 (en) *	1999-07-09	2002-09-10	Bpsi Holdings, Inc.	Film coatings and film coating compositions based on polyvinyl alcohol
SK7292002A3 (en) *	1999-10-29	2002-12-03	Smithkline Beecham Corp	Pharmaceutical composition with controlled release for increasing the dose or system exposure of a medicament inhibiting pde4
US7182953B2 (en)	1999-12-15	2007-02-27	Celgene Corporation	Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
WO2003041326A2 (en)	2001-11-09	2003-05-15	Matsushita Electric Industrial Co., Ltd.	Moving picture coding method and apparatus
MY140561A (en) *	2002-02-20	2009-12-31	Nycomed Gmbh	Dosage form containing pde 4 inhibitor as active ingredient
US7276529B2 (en)	2002-03-20	2007-10-02	Celgene Corporation	Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en)	2002-03-20	2005-11-08	Celgene Corporation	(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en)	2002-03-20	2007-04-24	Celgene Corporation	Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
AU2003222034A1 (en)	2002-03-20	2003-10-08	Celgene Corporation	(-)-2-(1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl)-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en)	2002-03-20	2011-02-22	Celgene Corporation	Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7393862B2 (en)	2002-05-17	2008-07-01	Celgene Corporation	Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7968569B2 (en)	2002-05-17	2011-06-28	Celgene Corporation	Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7323479B2 (en)	2002-05-17	2008-01-29	Celgene Corporation	Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7189740B2 (en)	2002-10-15	2007-03-13	Celgene Corporation	Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en)	2002-10-24	2005-09-15	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en)	2002-10-31	2004-05-13	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en)	2002-11-06	2009-07-21	Celgene Corporation	Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US20050100529A1 (en)	2003-11-06	2005-05-12	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
JP5089170B2 (ja)	2003-12-02	2012-12-05	セルジーンコーポレイション	異常ヘモグロビン症及び貧血症の治療及び管理のための方法及び組成物
US20050143344A1 (en)	2003-12-30	2005-06-30	Zeldis Jerome B.	Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
BRPI0509019A (pt)	2004-03-22	2007-08-07	Celgene Corp	métodos para tratar, prevenir ou controlar um distúrbio ou doença de pele, para tratar, prevenir ou controlar ceratose senil e para tratar ou controlar ceratose, composição farmacêutica, forma de dosagem unitária individual, e, kit
US20050222209A1 (en)	2004-04-01	2005-10-06	Zeldis Jerome B	Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
CN101163489A (zh)	2004-04-23	2008-04-16	细胞基因公司	用于治疗和控制肺高血压的包含免疫调节化合物的组合物及其使用方法
BRPI0517481A (pt)	2004-11-12	2008-10-14	Celgene Corp	método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica
ZA200704890B (en)	2004-11-23	2008-09-25	Celgene Corp	Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
KR20070090227A (ko)	2004-12-01	2007-09-05	셀진 코포레이션	면역조절 화합물을 포함하는 조성물 및 이의 면역결핍성장애의 치료를 위한 용도
US20060183766A1 (en) *	2005-02-15	2006-08-17	Wyeth	Orally bioavailable CCI-779 formulations
AU2006224760A1 (en) *	2005-03-17	2006-09-21	Synthon B.V.	Pharmaceutical tablets of crystalline Type II aripiprazole
WO2006111980A2 (en)	2005-04-20	2006-10-26	Ideal Cures Pvt. Ltd.	Pva based film coating and film coating compositions
RS51840B (sr)	2005-09-01	2012-02-29	Celgene Corporation	Imunološke primene imunomodulatornih jedinjenja za vakcinu i za terapiju protiv infektivnih bolesti
US20070155791A1 (en)	2005-12-29	2007-07-05	Zeldis Jerome B	Methods for treating cutaneous lupus using aminoisoindoline compounds
US8927546B2 (en) *	2006-02-28	2015-01-06	Dart Neuroscience (Cayman) Ltd.	Therapeutic piperazines
DK2276483T3 (da) *	2008-03-27	2014-06-10	Celgene Corp	Faste former, omfattende (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindolin-1,3-dion, sammensætninger deraf og anvendelser deraf
DE102008047910A1 (de) *	2008-09-19	2010-03-25	Molkerei Meggle Wasserburg Gmbh & Co. Kg	Tablettierhilfsstoff auf Laktose- und Cellulosebasis
EP2196465A1 (en) *	2008-12-15	2010-06-16	Almirall, S.A.	(3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
CN102387798A (zh)	2009-02-10	2012-03-21	细胞基因公司	供治疗、预防和控制结核病的pde4调节剂的使用方法及包含其的组合物
RU2558798C2 (ru) *	2009-11-13	2015-08-10	Астразенека Аб	Составы таблетки с немедленным высвобождением
CA2777719A1 (en)	2009-11-19	2011-05-26	Celgene Corporation	Apremilast for the treatment of sarcoidosis
ES2753198T5 (es) *	2010-12-16	2023-05-31	Amgen Europe Gmbh	Formas farmacéuticas orales de liberación controlada de fármacos poco solubles y sus usos
PL3756650T3 (pl)	2011-12-27	2026-01-19	Amgen (Europe) GmbH	Formulacje (+)-2-[1-(3-etoksy-4-metoksy-fenylo)-2-metanosulfonylo-etylo]-4-acetyloaminoizoindolino-1,3-dionu

2012
- 2012-12-26 PL PL20172615.5T patent/PL3756650T3/pl unknown
- 2012-12-26 SG SG11201403564YA patent/SG11201403564YA/en unknown
- 2012-12-26 ES ES12808662T patent/ES2799448T3/es active Active
- 2012-12-26 CA CA2861594A patent/CA2861594A1/en active Pending
- 2012-12-26 KR KR1020147020953A patent/KR102035362B1/ko active Active
- 2012-12-26 SI SI201231796T patent/SI2797581T1/sl unknown
- 2012-12-26 DK DK12808662.6T patent/DK2797581T3/da active
- 2012-12-26 AU AU2012362562A patent/AU2012362562B2/en active Active
- 2012-12-26 WO PCT/US2012/071623 patent/WO2013101810A1/en not_active Ceased
- 2012-12-26 LT LTEP20172615.5T patent/LT3756650T/lt unknown
- 2012-12-26 UA UAA201408510A patent/UA113750C2/uk unknown
- 2012-12-26 LT LTEP12808662.6T patent/LT2797581T/lt unknown
- 2012-12-26 US US13/727,366 patent/US20130164376A1/en not_active Abandoned
- 2012-12-26 HR HRP20200825TT patent/HRP20200825T1/hr unknown
- 2012-12-26 RS RS20200715A patent/RS60415B1/sr unknown
- 2012-12-26 EP EP25181548.6A patent/EP4623993A3/en active Pending
- 2012-12-26 KR KR1020197030218A patent/KR102232154B1/ko active Active
- 2012-12-26 PE PE2014001038A patent/PE20142318A1/es not_active Application Discontinuation
- 2012-12-26 EA EA201491292A patent/EA027801B1/ru not_active IP Right Cessation
- 2012-12-26 FI FIEP20172615.5T patent/FI3756650T3/fi active
- 2012-12-26 HU HUE12808662A patent/HUE050327T2/hu unknown
- 2012-12-26 SG SG10201605251VA patent/SG10201605251VA/en unknown
- 2012-12-26 MX MX2014007878A patent/MX373934B/es active IP Right Grant
- 2012-12-26 ES ES20172615T patent/ES3049175T3/es active Active
- 2012-12-26 SM SM20200339T patent/SMT202000339T1/it unknown
- 2012-12-26 SI SI201232098T patent/SI3756650T1/sl unknown
- 2012-12-26 PT PT201726155T patent/PT3756650T/pt unknown
- 2012-12-26 RS RS20251057A patent/RS67339B1/sr unknown
- 2012-12-26 HU HUE20172615A patent/HUE073430T2/hu unknown
- 2012-12-26 KR KR1020217008170A patent/KR20210033073A/ko not_active Ceased
- 2012-12-26 JP JP2014550424A patent/JP6161629B2/ja active Active
- 2012-12-26 SM SM20250402T patent/SMT202500402T1/it unknown
- 2012-12-26 CN CN201280070694.5A patent/CN104136003A/zh active Pending
- 2012-12-26 PL PL12808662T patent/PL2797581T3/pl unknown
- 2012-12-26 BR BR112014015923-8A patent/BR112014015923B1/pt active IP Right Grant
- 2012-12-26 HR HRP20251291TT patent/HRP20251291T1/hr unknown
- 2012-12-26 PT PT128086626T patent/PT2797581T/pt unknown
- 2012-12-26 EP EP12808662.6A patent/EP2797581B1/en not_active Revoked
- 2012-12-26 EP EP20172615.5A patent/EP3756650B1/en active Active
- 2012-12-26 DK DK20172615.5T patent/DK3756650T3/da active
2014
- 2014-06-22 IL IL233296A patent/IL233296B/en active IP Right Grant
- 2014-06-24 ZA ZA2014/04629A patent/ZA201404629B/en unknown
- 2014-06-26 NI NI201400068A patent/NI201400068A/es unknown
- 2014-06-26 CL CL2014001726A patent/CL2014001726A1/es unknown
- 2014-06-26 MX MX2020005145A patent/MX2020005145A/es unknown
- 2014-06-27 PH PH12014501495A patent/PH12014501495A1/en unknown
- 2014-06-27 CR CR20140314A patent/CR20140314A/es unknown
- 2014-07-03 EC ECIEPI20147965A patent/ECSP14007965A/es unknown
- 2014-07-09 CO CO14147911A patent/CO7000777A2/es unknown
2020
- 2020-05-14 US US16/874,424 patent/US12576034B2/en active Active
- 2020-06-25 CY CY20201100590T patent/CY1123174T1/el unknown

Also Published As

Publication number	Publication date
UA113750C2 (xx)	2017-03-10
SMT202500402T1 (it)	2025-11-10
CL2014001726A1 (es)	2014-11-14
EP4623993A2 (en)	2025-10-01
PT3756650T (pt)	2025-10-28
IL233296B (en)	2018-11-29
EP3756650B1 (en)	2025-08-20
HUE050327T2 (hu)	2020-11-30
HK1202056A1 (en)	2015-09-18
NZ626615A (en)	2016-08-26
HRP20200825T1 (hr)	2020-08-07
JP6161629B2 (ja)	2017-07-12
CY1123174T1 (el)	2021-10-29
HRP20251291T1 (hr)	2025-12-05
EP3756650A1 (en)	2020-12-30
MX2020005145A (es)	2020-08-17
ES2799448T3 (es)	2020-12-17
SG10201605251VA (en)	2016-08-30
FI3756650T3 (fi)	2025-10-30
PH12014501495B1 (en)	2014-09-22
AU2012362562B2 (en)	2017-11-02
LT3756650T (lt)	2025-11-10
PE20142318A1 (es)	2015-01-16
ZA201404629B (en)	2017-08-30
SMT202000339T1 (it)	2020-07-08
KR102035362B1 (ko)	2019-10-22
EP2797581B1 (en)	2020-05-06
ES3049175T3 (en)	2025-12-15
MX373934B (es)	2020-07-10
KR20210033073A (ko)	2021-03-25
EA201491292A1 (ru)	2014-11-28
MX2014007878A (es)	2015-03-23
DK3756650T3 (da)	2025-11-03
NI201400068A (es)	2016-01-28
IL233296A0 (en)	2014-08-31
CA2861594A1 (en)	2013-07-04
PH12014501495A1 (en)	2014-09-22
US20210093573A1 (en)	2021-04-01
KR102232154B1 (ko)	2021-03-25
SI3756650T1 (sl)	2026-01-30
EA027801B1 (ru)	2017-09-29
BR112014015923B1 (pt)	2022-02-01
DK2797581T3 (da)	2020-07-20
RS67339B1 (sr)	2025-11-28
BR112014015923A8 (pt)	2017-07-04
KR20190120418A (ko)	2019-10-23
US20130164376A1 (en)	2013-06-27
US12576034B2 (en)	2026-03-17
PL3756650T3 (pl)	2026-01-19
CO7000777A2 (es)	2014-07-21
SI2797581T1 (sl)	2020-08-31
CN104136003A (zh)	2014-11-05
PT2797581T (pt)	2020-06-18
HUE073430T2 (hu)	2026-01-28
BR112014015923A2 (pt)	2017-06-13
AU2012362562A1 (en)	2014-07-17
CR20140314A (es)	2014-10-28
RS60415B1 (sr)	2020-07-31
SG11201403564YA (en)	2014-07-30
LT2797581T (lt)	2020-07-10
WO2013101810A1 (en)	2013-07-04
KR20140108707A (ko)	2014-09-12
EP4623993A3 (en)	2025-12-17
ECSP14007965A (es)	2015-11-30
JP2015506356A (ja)	2015-03-02
EP2797581A1 (en)	2014-11-05

Publication	Publication Date	Title
PL2797581T3 (pl)	2020-10-05	Formulacje (+)-2-[1-(3-etoksy-4-metoksy-fenylo)-2-metanosulfonylo-etylo]- 4acetyloaminoizoindolino-1,3-dionu
HRP20190118T1 (hr)	2019-03-08	Novi imunokonjugati
CO6862160A2 (es)	2014-02-10	Indazoles
DK2768479T3 (da)	2020-08-10	Hjælpestoffer til nikotin-indeholdende terapeutiske sammensætninger
EP2799171A4 (en)	2015-08-05	DRILL
EP2796109A4 (en)	2015-10-07	DENTAL MEMBRANE
EP2684630A4 (en)	2014-08-13	DRILL
EP2774704A4 (en)	2015-07-22	DRILL
EP2877458A4 (en)	2016-08-10	CYSTATHIONINE-Y-GAMMA-LYASE (CSE) -HEMMER
ZA201403969B (en)	2015-05-27	2-(substituted-phenyl)=cyclopentane-1,3-dione compounds, and derivatives thereof
HRP20160887T1 (hr)	2016-09-23	Formulacije testosterona
EP2754518A4 (en)	2015-04-22	DRILL
CO6950470A2 (es)	2014-05-20	Formulaciones derivadas de decitabina
CO6940426A2 (es)	2014-05-09	Formulaciones farmacéuticas
CR20140068A (es)	2014-08-18	Una formulación herbicida mejorada
ITTO20121129A1 (it)	2013-06-28	Procedimento per la protezione di mais.
DK2572579T3 (da)	2014-07-28	Sammensætninger til at tiltrække tortricidae (viklere)
DK2672817T3 (da)	2017-11-20	Forbedrede insekticide formuleringer
ITTO20121127A1 (it)	2013-06-28	Procedimento per la protezione di mais.
EP2717853A4 (en)	2014-11-05	Gel compositions
PL2696846T3 (pl)	2018-06-29	Doustne dyspersyjne kompozycje farmaceutyczne
TH1401003680A (th)	2016-11-07	สูตรผสมของ (+)-2-[1-(3-อีธอกซิ-4-เมธอกซิ-ฟีนิล)-2-มีเธนซัลโฟนิล-เอธิล]-4- อะซิติลอะมิโนไอโซอินโดไลน์-1,3-ไดโอน
ES1075472Y (es)	2012-01-26	Fregadero integral
DK2494862T3 (da)	2013-11-18	Såskær
FI9425U1 (fi)	2011-10-21	Huoltokaivo